PDCD1 and colorectal carcinoma: Additionally, the combined application of Bifidobacterium and Enterococcus faecalis enhances the anti‐PD‐1 therapeutic effect, likely by improving the intestinal inflammatory environment and systemic T cell activity, thereby potentially preventing the development of resistance to ICIs in dMMR CRC patients [105].